Open company graph database — free web & API
Login

SymBio Pharmaceuticals Inc.

シンバイオ製薬株式会社SymBio Pharmaceuticals LimitedAlias
Ticker
Listed market
TYO
Country
Japan
Employees (non-consolidated)
101
Related companies
1
§01

Basic information

BASIC
Head office
7th Floor, Toranomon Towers Office, 1-28 Toranomon 4-chome, Minato-ku, Tokyo 105-0001, Japan
Chief executive
Fumiki Yoshida
Capital
19,244,128,000  (192 100 million)
Employees (non-consolidated)
101 people
Employees (consolidated)
Start date
2005-03-25
End date
§02

Websites

1 DOMAINS
§03

Business

2
Independent drug discovery businessCollaborative research with academia
§04

Related companies

1 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
SymBio Pharma USA, Inc.
Group
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

55 EVENTS

SymBio Pharmaceuticals Limited established at Nishi-Shimbashi, Minato-ku, TokyoSources

SymBio Pharmaceuticals Co., Ltd. established in Nishi-Shimbashi, Minato-ku, Tokyo.Sources

Head office relocates to Shimbashi, Minato-ku, TokyoSources

Head office moved to Shimbashi, Minato-ku, Tokyo.Sources

License Agreement finalized with Astellas Pharma GmbH for SyB L-0501 (bendamustine) development & commercialization rights in JapanSources

Entered into a license agreement with Astel Pharma (Germany) for exclusive development and sale of the anticancer agent 'Bendamustine Hydrochloride' in Japan.Sources

Manufacturer's License (packaging, labeling and storage) obtained from Tokyo Metropolitan GovernmentSources

Obtained a permit from the Tokyo Metropolitan Government for pharmaceutical manufacturing (packaging, labeling, storage) (Permit No.: 13AZ200010).Sources

License Agreement finalized with Astellas Deutschland GmbH for SyB L-0501 (bendamustine) development & commercialization rights in China (HK), Taiwan, Korea and SingaporeSources

Entered into a license agreement with Astel Dichtlants (Germany) for exclusive development and sale of the anticancer agent 'SyB L-0501' in China, Korea, Taiwan, and Singapore.Sources

License Agreement finalized with Eisai Co., Ltd. for co-development and commercialization rights of SyB L-0501 (bendamustine) in JapanSources

Entered into a license agreement with Eisai Co., Ltd. regarding the anticancer agent 'SyB L-0501'.Sources

SymBio Pharmaceuticals concludes Sublicense Agreement with Cephalon, Inc. for development and commercialization rights of bendamustine hydrochloride in China (HK)Sources

Entered into a sublicense agreement with Cefalon Inc. (USA) granting development and commercialization rights for the anticancer agent 'SyB L-0501' in China.Sources

License Agreement finalized with Eisai Co., Ltd. for co-development and commercialization rights of SyB L-0501 (bendamustine) in Korea and SingaporeSources

Entered into a license agreement with Eisai Co., Ltd. for the anticancer agent 'SyB L-0501' targeting Korea and Singapore.Sources

Received Domestic Manufacturing and Marketing Approval for Anticancer Agent TREAKISYMSources

Obtained domestic manufacturing and sales approval for the anticancer agent 'TREAKISYM : ® :'.Sources

Launched domestic sales of anticancer agent TREAKISYMSources

Commenced domestic sales of the anticancer agent 'TREAKISYM : ® :'.Sources

Held a press conference for the establishment of Symbio Pharmaceutical Co., Ltd.Sources

Onconova and SymBio Pharmaceuticals complete License Agreement for SyB L-1101/SyB C-1101Sources

Entered into a license agreement with Oncova Inc. (USA) regarding the anticancer agents 'SyB L-1101/SyB C-1101'.Sources

Listed on Osaka Securities Exchange JASDAQ Growth MarketSources

Listed on the Osaka Stock Exchange JASDAQ Growth market.Sources

Head office relocates to Toranomon, Minato-ku, TokyoSources

Head office moved to Toranomon, Minato-ku, Tokyo.Sources

SymBio Pharma USA, Inc. established at Menlo Park, California, USASources

SymBio Pharma USA, Inc. (SymBio Pharma USA Inc.) established in Menlo Park, California, USA.Sources

Established SymBio Pharma USA, Inc. in Menlo Park, California, USA.Sources

Approval for Domestic Manufacturing and Marketing of Anticancer Agent TREAKISYM for Additional Indication of Chronic Lymphocytic LeukemiaSources

Obtained domestic manufacturing and sales approval for the additional efficacy of the anticancer agent 'TREAKISYM : ® :' against chronic lymphocytic leukemia.Sources

SymBio Pharmaceuticals announces the NDA approval of TREAKISYM (bendamustine) for the additional indication of First-line Treatment of Low-grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma in JapanSources

Obtained domestic manufacturing and sales approval for the additional efficacy of the anticancer agent Treaxin® for untreated low-grade non-Hodgkin lymphoma and mantle cell lymphoma.Sources

Eagle Pharmaceuticals (NASDAQ: EGRX) and SymBio Pharmaceuticals completed License Agreement for bendamustine liquid formulations (RTD Injection and RI Injection) development & commercialization rights in Japan *RTD: Ready-to-dilute, RI: Rapid InfusionSources

Entered an exclusive licensing agreement with Eagle Pharmaceuticals (USA) for the development and commercialization of Bendamustine liquid formulations (RTD and RI) in Japan.Sources

TREAKISYM (bendamustine) has been newly included as a standard-of-care option in the Guidelines for Tumors of Hematopoietic and Lymphoid Tissues 2018Sources

Treaxin® was newly included as a standard treatment option in the 2018 edition of the Hematologic Tumor Treatment Guidelines.Sources

Treaxin® was newly included as a standard treatment option in the 2018 edition of the Hematologic Tumor Treatment Guidelines.Sources

September 2019: Chimerix (USA) and anti-viral drug 'Brinshidohobiru' (excluding smallpox) entered into an exclusive global license agreement for development, sales, and manufacturingSources

Entered an exclusive global licensing agreement with Chimerix (USA) for the development, sale, and manufacture of the antiviral drug Brinshidobiv (excluding smallpox).Sources

SymBio Pharmaceuticals receives approval of TREAKISYM Ready-To-Dilute (RTD) formulationSources

Obtained approval for the manufacturing and sales of Treaxin® liquid formulation (RTD).Sources

Commencement of in-house sales of the anti-cancer agent TREAKISYM : ®Sources

Commenced in-house sales of the anticancer agent Treaxin®.Sources

Market Launch of TREAKISYM : ® : Ready-To-Dilute (RTD) FormulationSources

Released Treaxin® liquid formulation (RTD).Sources

SymBio Pharmaceuticals receives approval of TREAKISYM : ® : (bendamustine) in combination with rituximab, and in combination with rituximab and polatuzumab vedotin for relapsed or refractory diffuse large B-cell lymphomaSources

Obtained approval for the combination therapy of Treaxin® and rituximab for relapsed or refractory diffuse large B-cell lymphoma, and also approval for the combination therapy of Treaxin®, rituximab, and polatuzumab vedotin.Sources

SymBio Pharmaceuticals receives approval of TREAKISYM : ® : Ready-To-Dilute (RTD) Formulation in combination with rituximab ,and in combination with rituximab and polatuzumab vedotin for relapsed or refractory diffuse large B-cell lymphomaSources

Obtained approval for the combination therapy of Treaxin® liquid formulation (RTD) and rituximab for relapsed or refractory diffuse large B-cell lymphoma, and also approval for the combination therapy of Treaxin® liquid formulation (RTD), rituximab, and polatuzumab vedotin.Sources

SymBio Pharmaceuticals receives approval of 10-minute Rapid Infusion (RI) administration of the TREAKISYM : ® : Liquid FormulationSources

Obtained approval for the Treaxin® liquid formulation (RI administration, 10-minute infusion).Sources

Head office relocates within Toranomon, Minato-ku, TokyoSources

Relocated headquarters to Toranomon, Minato-ku, Tokyo.Sources

§07

News

839 ARTICLES

Minori Rosales Appointed Executive Officer and Head of Japan DevelopmentSources

Syngbio Pharmaceuticals Inc. appointed Mr. Minori Rosales as Executive Officer and Head of Japan Development as of January 1, 2026. Mr. Rosales, who has experience in oncology as a CMO, will play a role in integrating the Japanese and U.S. research and development divisions. The company is shifting its business strategy toward global expansion and has outlined a plan to strengthen the global rollout of IV BCV.

Monthly Exercise Status of Third-Party Allocated Stock Option WarrantsSources

The 65th stock option was granted 3,650,000 shares, 107 were exercised on December 1, and the unexercised balance is 93,200. The 58th stock option had 0 shares granted, 0 exercised, and the unexercised balance remains 20,000.

Mass Exercise of the 65th Series of Stock OptionsSources

Symbio Pharmaceuticals announced that 27,000 units (13.5% of the total issued) of the 65th series of stock options, issued through a third‑party allocation, were exercised at the beginning of the month, resulting in the issuance of 2,700,000 shares. As of January 15, 66,200 options remained unexercised.

SymBio Pharmaceuticals Takes a New Approach to Treating Multiple Sclerosis with IV BCVSources

SymBio Pharmaceuticals Limited, in collaboration with the U.S. NIH’s NINDS, evaluated the effects of IV BCV (brincidofovir for injection). The findings were published in the Journal of Clinical Investigation and confirmed that low-dose BCV markedly suppresses Epstein-Barr virus activity and selectively inhibits only Epstein-Barr virus-positive B-cell lymphocytes.

Symbio Pharmaceuticals Announces Start of PML Treatment Clinical Trial with NIH under CRADASources

Symbio Pharmaceuticals Inc. has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. National Institutes of Health (NIH) and announced the initiation of a pilot clinical trial of IV BCV targeting progressive multifocal leukoencephalopathy (PML). The trial will be conducted at the NIH Clinical Center's NINDS Immunotherapy Research Unit and will evaluate the efficacy and safety of IV BCV in 18 PML patients.

Monthly Exercise Status Report for Third-Party Allocation of Stock Purchase RightsSources

In the 65th issuance of stock purchase rights, 4,510,000 shares were granted, and 45,100 rights (22.6%) were exercised. In the 58th issuance, no shares were granted and no rights were exercised. The unexercised balance is 48,100 rights for the 65th issuance and 20,000 rights for the 58th issuance.

FY 2025 December Quarterly Financial SummarySources

The consolidated sales for FY 2025 December quarter decreased by 46.7% compared to the previous period. Operating loss was 4.44 billion yen, and ordinary loss was 4.67 billion yen, both expanding from the prior period. The diluted earnings per share for the period were 95.12 yen.

IV BCV Phase II Trial Results Presented at TandemSources

Symbiopharma announced that it orally presented the Phase II clinical trial results of IV BCV (intravenous Brinshidovir) targeting CMV infection in patients with immune deficiency following hematopoietic stem cell transplantation at the Tandem Meetings. The trial enrolled 19 patients, including those who continued to have CMV viremia after prior therapy, and evaluated the efficacy and safety of IV BCV administered twice weekly at different doses.

Symbio Pharma FY2025 December Quarterly Earnings PresentationSources

This document is the earnings presentation for Symbio Pharma Co., Ltd. for the fiscal year ending December 2025. Part 1 outlines the business strategy rollout, Part 2 presents the financial overview for FY2025, and Part 3 provides a forecast for the full year of FY2026. Key highlights include the initiation of the NIH-led Phase II clinical trial for PML, the start of a global Phase III trial for adenovirus infections, development activities in oncology, the signing of a global exclusive license agreement with a U.S. university, and the expansion of the IVD business.

Completion of Exercise of the 65th Stock Option GrantSources

During the target month, 48,100 shares of the 65th stock option grant were exercised, resulting in the issuance of 4,810,000 common shares. The exercise ratio relative to the total issued shares was 24.1%, and there were no unexercised stock options remaining at the end of the target month, marking the completion of the exercise.

§08

Public records

GOV
National Tax Agency basic information1010401057034
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
シンバイオ製薬株式会社
Trade name (kana)
シンバイオセイヤク
Name in English
Corporation type
301
Address
〒105-0001 東京都港区虎ノ門4丁目1番28号
Postal code
1050001
Prefecture code
13
City code
103
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2023-12-04
Change date
2023-12-01
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
1298574
METI gBizINFO1010401057034
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
1010401057034
Trade name
シンバイオ製薬株式会社
Trade name (kana)
シンバイオセイヤク
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都港区虎ノ門4丁目1番28号
Postal code
1050001
Prefecture
東京都
Prefecture code
13
City or district
港区
City code
103
Street address
虎ノ門4丁目1番28号
Organisation type
301
Processing type
12
Correction type
0
Status
Representative
代表取締役社長兼CEO    吉田  文紀
Capital
19244128000
Employees
150
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
E:製造業
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2023-12-04
Key information
1010401057034
§09

Sources & updates

SOURCES
↑